Rhumbline Advisers Has $130,000 Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Rhumbline Advisers reduced its stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) by 13.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,879 shares of the company’s stock after selling 1,950 shares during the quarter. Rhumbline Advisers owned about 0.05% of Artiva Biotherapeutics worth $130,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. RA Capital Management L.P. bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $152,234,000. Franklin Resources Inc. bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $7,435,000. Geode Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $4,774,000. Samsara BioCapital LLC bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $4,506,000. Finally, Wellington Management Group LLP bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $2,912,000.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. HC Wainwright assumed coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They set a “buy” rating and a $20.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $21.00.

Artiva Biotherapeutics Stock Performance

NASDAQ ARTV opened at $5.31 on Tuesday. The stock’s 50 day moving average price is $5.95 and its two-hundred day moving average price is $9.85. Artiva Biotherapeutics, Inc. has a 52 week low of $3.37 and a 52 week high of $17.31.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.